Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
Mach M, Bazydło-Guzenda K, Buda P, Matłoka M, Dzida R, Stelmach F, Gałązka K, Wąsińska-Kałwa M, Smuga D, Hołowińska D, Dawid U, Gurba-Bryśkiewicz L, Wiśniewski K, Dubiel K, Pieczykolan J, Wieczorek M. Mach M, et al. Eur J Med Chem. 2021 Dec 15;226:113810. doi: 10.1016/j.ejmech.2021.113810. Epub 2021 Sep 1. Eur J Med Chem. 2021. PMID: 34537444
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.
Matłoka M, Janowska S, Gajos-Draus A, Ziółkowski H, Janicka M, Perko P, Kamil K, Pankiewicz P, Moszczyński-Pętkowski R, Mach M, Dera P, Abramski K, Teska-Kamińska M, Tratkiewicz E, Wieczorek M, Pieczykolan J. Matłoka M, et al. Among authors: mach m. Pulm Pharmacol Ther. 2022 Jun;73-74:102127. doi: 10.1016/j.pupt.2022.102127. Epub 2022 Apr 14. Pulm Pharmacol Ther. 2022. PMID: 35429651
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: mach m. Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949. Pharmaceuticals (Basel). 2022. PMID: 36015098 Free PMC article.
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.
Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U, Mulewski K, Smuga D, Maruszak W, Gurba-Bryśkiewicz L, Leniak A, Pietruś W, Ochal Z, Mach M, Zygmunt B, Pieczykolan J, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: mach m. Pharmaceuticals (Basel). 2022 Jul 27;15(8):927. doi: 10.3390/ph15080927. Pharmaceuticals (Basel). 2022. PMID: 36015075 Free PMC article.
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J. Bazydlo-Guzenda K, et al. Among authors: mach m. Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4. Mol Pharmacol. 2021. PMID: 34349026